Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease

Wang, Pengzhen, Zheng, Xiaoyao, Guo, Qian, Yang, Peng, Pang, Xiaoying, Qian, Kang, Lu, Wei, Zhang, Qizhi, Jiang, Xinguo·2018·Journal of Controlled Release

Abstract

ABSTRACT &bgr;‐site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme to cleave the amyloid precursor protein to develop Alzheimer's disease (AD). Reducing BACE1 expression in central neuron through RNA interference technology shows great promise to overcome AD. However, to obtain an efficient and neurons‐specific delivery of siRNA against BACE1 through systemic administration remains challenging. Here, we design and prepare siRNA nano‐carriers based on PEGylated poly(2‐(N,N‐dimethylamino) ethyl methacrylate) (PEG‐PDMAEMA) modified with both the CGN peptide for blood‐brain barrier (BBB) penetration and the Tet1 peptide for neuron‐specific binding. The nanocomplexes CT/siRNA, composed of CGN‐PEG‐PDMAEMA and Tet1‐PEG‐PDMAEMA at a weight ratio of 1:1, display a good stability in the blood and do not lead to hemolysis at N/P=10. The internalization of nanocomplexes in neuron cells relies on clathrin‐mediated endocytosis and micropinocytosis, while caveolae‐mediated endocytosis plays a major role in entrance of CT/siRNA into cerebral capillary endothelial cell bEnd.3. The nanocomplexes successfully escape from lysosomes and enter in the cytoplasm of the neuron cells, inducing effective gene silence (about 50% decrease in BACE1 mRNA levels) and reversing A&bgr;25–35 oligomer‐induced synaptic injury. After caudal vein injection in mice, CT/siRNA display higher brain accumulation than unmodified nanocomplexes (brain drug targeting index=2.62), and colocalize with neurons or locate nearby. In APP/PS1 transgenic mice, the nanocomplexes significantly decrease BACE1 mRNA and the amyloid plaques, suppress phosphorylated tau protein levels, as well as promote hippocampal neurogenesis. Noticeably, administration of the nanocomplexes restores the cognitive performance of the AD transgenic mice to the level of wild‐type control without significant adverse effects on myelination. Our results demonstrate the CT/siRNA nanocomplexes capable of specifically directing BACE1 siRNA to brain neurons with great potential for AD therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2018.04.034

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 158

Metadata

Authors
Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2018-06
Volume
279
Pages
220-233
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2801318634
Cited by
158
References
6
FWCI
3.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jconrel.2018.04.034
The paper
Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X. (2018). Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2018.04.034

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.